Log in
NASDAQ:AGLE

Aeglea Bio Therapeutics Stock Forecast, Price & News

$8.04
-0.11 (-1.35 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$7.55
Now: $8.04
$8.22
50-Day Range
$6.74
MA: $7.46
$8.19
52-Week Range
$3.50
Now: $8.04
$11.38
Volume216,204 shs
Average Volume213,822 shs
Market Capitalization$358.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB4104, a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocysteine; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More
Aeglea Bio Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGLE
CUSIPN/A
Phone512-942-2935
Employees61

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.89 million
Book Value$2.07 per share

Profitability

Net Income$-78,250,000.00

Miscellaneous

Market Cap$358.58 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$8.04
-0.11 (-1.35 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions

How has Aeglea Bio Therapeutics' stock price been impacted by COVID-19?

Aeglea Bio Therapeutics' stock was trading at $5.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have increased by 49.4% and is now trading at $8.04.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aeglea Bio Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aeglea Bio Therapeutics
.

When is Aeglea Bio Therapeutics' next earnings date?

Aeglea Bio Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aeglea Bio Therapeutics
.

How were Aeglea Bio Therapeutics' earnings last quarter?

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.40) EPS for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.03.
View Aeglea Bio Therapeutics' earnings history
.

What price target have analysts set for AGLE?

3 equities research analysts have issued 1-year price targets for Aeglea Bio Therapeutics' stock. Their forecasts range from $11.00 to $17.00. On average, they anticipate Aeglea Bio Therapeutics' stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 65.8% from the stock's current price.
View analysts' price targets for Aeglea Bio Therapeutics
.

Who are some of Aeglea Bio Therapeutics' key competitors?

What other stocks do shareholders of Aeglea Bio Therapeutics own?

Who are Aeglea Bio Therapeutics' key executives?

Aeglea Bio Therapeutics' management team includes the following people:
  • Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)
  • Mr. Charles N. York II, CFO & VP (Age 42)
  • Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)
  • Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)
  • Mr. Eugene Sackett, VP of HR

When did Aeglea Bio Therapeutics IPO?

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea Bio Therapeutics' stock symbol?

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea Bio Therapeutics' major shareholders?

Aeglea Bio Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.27%).
View institutional ownership trends for Aeglea Bio Therapeutics
.

Which institutional investors are selling Aeglea Bio Therapeutics stock?

AGLE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A..
View insider buying and selling activity for Aeglea Bio Therapeutics
.

How do I buy shares of Aeglea Bio Therapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aeglea Bio Therapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $8.04.

How big of a company is Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics has a market capitalization of $358.58 million and generates $3.89 million in revenue each year. The biotechnology company earns $-78,250,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe.

What is Aeglea Bio Therapeutics' official website?

The official website for Aeglea Bio Therapeutics is www.aegleabio.com.

How can I contact Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]

This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.